Fontan Global Case Conference Richard J. Czosek, MD 6/28/17

Slides:



Advertisements
Similar presentations
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Advertisements

Arrhythmias Post Tetralogy of Fallot Surgical Repair
{ Cardioversion turns 50 Seth Bilazarian MD Private practice theheart.org.
Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Patients with suspected syncope should be investigated by cardiologists Dr NR Stout.
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
Congenital Heart Disease: Outcome in Patients with Single Ventricle
Implantable Cardioverter Defibrillator Rebecca Boduch Biomedical Engineering University of Rhode Island.
Arrhythmias: The Good, the Bad and the Ugly
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.
Audit of ablation procedures for AF Barts and The London.
Arrhytmia In Heart Failure
ACHD Patients Should Receive Treatment in Adult Institutions Society of Thoracic Surgeons Adult Cardiac Surgery Database reports 39,872 adults undergoing.
CARDIAC ARRHYTHMIA Charn Sriratanasathavorn, MD,FACC
Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Amiodarone Use in Cardiac Surgical Resuscitation
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Atrial Fibrillation Rate or rhythm control? Who should be anticoagulated? Other treatment strategies.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Atrial Fibrillation What is New in the 2006 ACC/AHA/ESC Guidelines HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation. May 2007.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Leonard Steinberg, MD Timothy Knilans, MD The Heart Center Children’s Hospital Medical Center Cincinnati, OH The diagnosis and management of supraventricular.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.
Fontan Procedure Ken Jusko, DO. Case 39 yo female with h/o tricuspid atresia and A. fib. and prior Fontan. No prior studies available for comparison.
Redo afib ablation John R Onufer MD FHRS
Asklepios Klink St. Georg, Hamburg
ARRHYTHMIA. Disturbance of cardiac rythumn Anatomy of the conducting system.
Catheter Ablation of Atrial Fibrillation in the Last 10 Years: Breakthroughs and Advances Dr. Feifan Ouyang Asklepios Klinik St. Georg Hamburg Sept. 19th,
Adult with operated congenital heart disease: what should we check for? January 15 th, h-17h30.
Rhythm and Rate Control for Atrial Fibrillation Tom Wallace, MD Cardiac Electrophysiology CHI St. Vincent Heart Clinic Arkansas.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
IN THE NAME OFGODIN THE NAME OFGOD SVTS.SAYAH.  All cardiac tachyarrhythmias are produced by: 1/disorders of impulse initiation :automatic 2/abnormalities.
THE HEART’S ELECTRICAL SYSTEM Marco Perez, MD Center for Inherited Cardiovascular Disease Inherited Cardiac Arrhythmia Clinic June 20, 2013.
Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.
Date of download: 7/9/2016 From: Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac.
Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation by Laurens F. Tops, Martin.
Ethical Scenario: Cardiovascular System
Atrial fibrillation J Heinsimer MD.
James S. Tweddell, MD Warren W. Bailey Endowed Chair,
Assessing for Baffle Stenosis using Intravascular Ultrasound
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Atrial Fibrillation: When Should You Consider Ablation?
Simon A. Castro, MD; Daniele Muser, MD; Erica Zado, PA; Rajeev K
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Next-generation sequencing increases the diagnostic yield in aborted sudden cardiac death caused by hereditary heart disease   Brøndberg AK1, Christiansen.
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
Bradycardias and Tachycardias
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
HYPERTROPHIC CARDIOMYOPATHY(HCM)
Dirty Laundry.
Emad B. Mossad, MD, Pablo Motta, MD, David F. Vener, MD 
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
The Outcome of the Cox Maze Procedure in Patients With Previous Percutaneous Catheter Ablation to Treat Atrial Fibrillation  Niv Ad, MD, Linda Henry,
PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.
Emad B. Mossad, MD, Pablo Motta, MD, David F. Vener, MD 
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
Risk Factor Modification
Cautery (ELECTRO MAGNETIC INTERFERENCE) & cardiac devices in endoscopy
Optimizing Atrial Fibrillation Management
Mahesh Anantha Narayanan et al. JACEP 2017;3:
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep
Long-term results of the lateral tunnel Fontan operation
Atrial Fibrillation: An Escalating Cardiovascular Disease With Significant Clinical and Economic Consequences.
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

Fontan Global Case Conference Richard J. Czosek, MD 6/28/17 The Role of Catheter Ablation in Fontan Arrhythmia Control: Patient Based Decision Making Fontan Global Case Conference Richard J. Czosek, MD 6/28/17

Patient 1 20 yo with non-fenestrated extra-cardiac Fontan who recently had their first episode of atrial tachycardia They were cardioverted without issue and are now on Coumadin Currently 3 months from this first episode of tachycardia currently on no anti-arrhythmic medications Patient 2 43 yo with a atrio-pulmonary Fontan with history of multiple cardioversions for atrial tachycardia with recent increase in symptomatology and 3-4 episodes in the past 12 months History previous ablation procedure 4 years prior Currently on Coumadin as well as amiodarone with continued breakthrough episodes of tachycardia

Prevalence of Atrial Flutter/IART in Fontan 1973 - 1991 Fishberger, et al., Jour. Thor. Card. Surgery, 1997

Role of Trans-catheter Ablation Medication DCCV Surgical Ablation Pacing Rate Control

Recurrence of Atrial Tachycardia Egbe et al., Int. Journ. Of Cardiology, 2016

Risk of Atrial Tachycardia Recurrence Egbe et al, American Heart Journal, 2017

To ablate or not to ablate Don’t Ablate

When to ablate? Ablation DCCV/ Pacing Fontan + Arrhythmia Medications/ Rate Control

Fontan Patient Decision Tools Trans-catheter Ablation Medications Surgical Ablation Medications Trans-catheter Ablation Surgical Ablation Decision Fontan Patient Atrial Arrhythmia Surgical Ablation Medications Decision Tools Patient Age Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Monitor for Recurrence Medications Trans-catheter Ablation

Trans-catheter Ablation Patient Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age

Trans-catheter Ablation Patient Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age

Atrial Arrhythmia and Fontan Type “Classic” Style Fontan Atrio-pulmonary Fontan Lateral Tunnel Fontan/Intra-atrial Conduit Extra-cardiac Conduit Fontan Fenestrated Kutty et al., Heart, 2015

Fontan Cardiac Type Fishberger, et al., Jour. Thor. Card. Surgery, 1997

Classic vs Lateral Tunnel Fontan Atrio-pulmonary Fontan Stamm et al., Journ. Thor. Card. Surgery, 2001

Effect of Fontan Type Balaji et al., Cong. Heart Disease, 2013

Atrio-pulmonary Fontan Effect of Fontan Type Extra-Cardiac Fontan Lateral Tunnel Fontan Atrio-pulmonary Fontan Pundi et al., Cong. Heart Disease, 2016

Collins et al, Amer. Heart Journal, 2000

Access to Tachycardia Substrate Kutty et al., Heart, 2015

Access in Differing Styles of Fontan Frequency of Tachycardia Classic Fontan Lateral Tunnel Extra-Cardiac Ease of Ablation Classic Fontan Lateral Tunnel Extra-Cardiac

Accessing Substrate In Extra-cardiac Fontan Moore et al., Heart Rhythm, 2016 Moore et al., Circulation Arr. Elect., 2015

Risks of Fontan Ablation Correa et al., JAHA, 2013

Risks of Fontan Ablation Correa et al., JAHA, 2013

Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age

Fontan Arrhythmia Mechanism Arrhythmias Number % of All (n=80) % of Ablations (n=59) Macro-reentrant 25 31% 42% Focal Atrial Tachycardia 8 10% 14% AVNRT 13 16% 22% AVRT 4 5% 7% VT 5 6% 8% Twin Node Undefined 21 26% n/a 57 procedures on 52 patients 80 arrhythmias identified Correa et al, Circ Arrhythm Electrophys, 2014

Atrial Fibrillation Takahashi et al, Europace, 2008

Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age

Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age

Risk Factors for SCD in Fontan Walsh E, et al, Heart Rhythm, 2014

Arrhythmia Influence on Fontan Diller et al, European Heart Journal, 2010

Risk of Mortality in Fontan Fontan Type Clinical arrhythmias Symptoms of heart failure Diller et al, Eur. Heart Journal, 2010

Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy

What is The Goal of Fontan Ablation? Hiroshi Nakagawa et al. Circulation, 2001

Outcomes in Fontan Patients With Atrial Arrhythmias Egbe et al, Amer. Heart Journal., 2016

Outcomes in Fontan Patients With Atrial Arrhythmias Egbe et al, Amer. Heart Journal., 2016

Correa et al., Circulation Arrhythmia Elect., 2015

Fontan Conversion/Arrhythmia Surgery Deal et al., Brit. Med. Journal, 2012

Risk of Atrial Tachycardia Recurrence Egbe et al, American Heart Journal, 2017

Trans-catheter Ablation Recurrent Atrial Arrhythmia Decision Patient Age Fontan Type Frequency of Tachycardia Patient Preference Fontan Patient Atrial Arrhythmia DCCV +/- Meds Recurrent Atrial Arrhythmia Surgical Ablation Decision Patient Age Fontan Type Patient Risk Factors Patient Preference Physician Preference Decision Patient Age Fontan Type Frequency of Tachycardia Patient Preference

Conclusions Fontan patients with SVT are likely to have recurrence of SVT Anti-arrhythmic medications are reasonable but unlikely to keep patients tachycardia free New onset Atrial Tachycardia or increased tachycardia burden is often an early indicator of other issues Catheter ablation plays a major role in management of SVT in Fontan patients and is reasonable as first or second line management We need to clearly define our goals The role of catheter ablation varies based on center and patient preference The role of catheter ablation is likely to change significantly over the next decades with change in Fontan anatomy

Patient 1 20 yo with non-fenestrated extra-cardiac Fontan who recently had their first episode of atrial tachycardia They were cardioverted without issue and are now on Coumadin Currently 3 months from this first episode of tachycardia currently on no anti-arrhythmic medications Question 1 Recommend catheter ablation as a first line treatment strategy Recommend monitoring without ablation or anti-arrythmic medication Recommend starting anti-arrhythmic medication without ablation Other

Patient 2 43 yo with a atrio-pulmonary Fontan with history of multiple cardioversions for atrial tachycardia with recent increase in symptomatology and 3-4 episodes in the past 12 months History previous ablation procedure 4 years prior Currently on Coumadin as well as amiodarone with continued breakthrough episodes of tachycardia Question 2 Recommend catheter ablation with continued anti- arrhythmic mediations Recommend monitoring without ablation or anti-arrythmic medication change Recommend starting a new anti-arrhythmic medication or changing anti-arrhythmic medication without ablation Other

Cincinnati Children's Hospital Medical Center

Sudden Death in Fontan Gallego et al, Amer. Journ. Card., 2012 Diller et al, European Heart Journal, 2010

Is There Disease Specific Risk of SCD? Gallego et al, Amer. Journ. Card., 2012

Sudden Death in Fontan’s Khairy et al., Circulation

Sudden Death in Fontan Pundi et al., Cong. Heart Disease, 2016

The Role of Surgical Ablation Deal et al., Brit. Med. Journal, 2012

Definition of Success in Fontan Ablation

Arrhythmic Influence on Single Fontan Diller et al, European Heart Journal, 2010

Fontan Arrhythmia Mechanism Arrhythmias Number % of All (n=80) % of Ablations (n=59) Macro-reentrant 25 31% 42% Focal Atrial Tachycardia 8 10% 14% AVNRT 13 16% 22% AVRT 4 5% 7% VT 5 6% 8% Twin Node Undefined 21 26% n/a 57 procedures on 52 patients 80 arrhythmias identified Access to pulmonary venous atrium Fenestration - 16 Trans-septal - 17 Retrograde - 2 Correa et al, Circ Arrhythm Electrophys, 2014